Long non-coding RNAs (lncRNAs) are a class of RNAs whose transcripts are more than 200 nucleotides in length and lack protein-coding ability. Taurine-upregulated gene 1 (TUG1), a novel cancer-related lncRNA, has been documented to be abnormally expressed in various types of cancers and act as an oncogene or anti-oncogene. It has been considered previously that TUG1 is closely related to the cell proliferation, invasion, metastasis, and apoptosis of cancer. In recent years, it has been found that TUG1 acts as a microRNA (miRNA) sponge to indirectly regulate the expression of the miRNA target gene and dominates cancer progression in several types of cancers. However, TUG1 also binds to different miRNAs to produce diverse regulatory mechanisms in the same cancer. TUG1 is expected to be a biomarker and a new therapeutic target for the diagnosis and prognosis of certain cancers. In this review, we highlight the up-to-date original studies that focus on the role of TUG1 sponging miRNA in cancers and summarize the function of TUG1 in cancer progression. The novel TUG1-miRNA regulatory network is comprehensively and minutely included in this review. We hope that this review will help readers obtain a more detailed knowledge of the molecular mechanism by which TUG1 sponging miRNA plays its role in cancers, and provide some insights and directions for future cancer research.
Introduction
As a major global public health problem, cancer has been one of the leading causes of death worldwide [1] . A study in 2015 showed that 90.5 million people have been diagnosed with cancer, with an annual increase of 14.1 million cases and 15.7% of people died of cancer [2, 3] . It is often difficult to diagnose cancer in the early stages due to non-significant and non-specific changes in the body and the lack of effective biomarkers. Therefore, further identification of biomarkers for cancer is vital for improving the initial diagnosis along with the treatment of cancer.
With the development of the human genome sequencing, it was found that only 1%-2% of the genes can be translated into proteins, and the rest are actively transcribed into non-coding RNAs (ncRNAs) [4, 5] . NcRNAs are conventionally divided into long ncRNAs (lncRNAs) that have more than 200 nucleotides in length and short ncRNAs including miRNA [6, 7] . LncRNAs are a novel class of RNA molecules that exert its physiological and pathological functions through interaction with genomic DNA, mRNA, miRNA, and protein [8, 9] . LncRNAs are important molecules in cell development and are involved in a series of cell evolutions such as parental imprinting, cell proliferation, and apoptosis through epigenetic modification, chromatin remodeling, and spongy miRNAs for metastasis [10, 11] . In recent years, a growing body of research has indicated that lncRNA also plays an important role in tumorigenesis, which is upregulated in several ways and thereby promotes tumor progression. Abnormally expressed lncRNA can be used as oncogene or tumor suppressor gene, which is closely related to tumor occurrence, prognosis and diagnosis [12, 13] . LncRNA is no longer the noise of genomic transcription, but it has become a research hotspot.
TUG1, a 7.1-kb lncRNA, was initially found to be expressed throughout retinal development in vitro [14, 15] . TUG1 is involved in cell proliferation, cell differentiation, cell invasion, drug resistance, radiation resistance, angiogenesis, and blood tumor barrier permeability regulation [16] . TUG1 is dysregulated in multiple cancers and acts as an oncogene or anti-oncogene in tumorigenesis and tumor development [17, 18] . TUG1 has been demonstrated to play important gene-regulatory roles through a variety of mechanisms, mainly by functioning as a miRNA sponge and interacting with PRC2. In the past few years, increasing lines of studies have been focusing on the novel competing endogenous RNA (ceRNA) regulatory mechanism that TUG1 competitively sponges miRNA and thus inhibits its function. Recently, TUG1 was found to be a biological indicator and a new therapeutic target for initial tumor diagnosis and target treatment.
MiRNA is a form of the 18-25 bp non-coding short RNA gene [19] . MiRNA plays a regulatory role in gene expression in animals and plants by pairing with the miRNAs of protein-coding genes to direct their post-transcriptional repression [20] . Mounting evidence suggested that TUG1 acts as an miRNA sponge and plays an essential role in the regulation of cancers. As a significant molecular sponge, TUG1 competitively binds to a variety of miRNAs, including miR-212-3p, miR-132-3p, miR-145, miR-26a, miR-9, miR-34a-5p, miR-382, miR-300, miR-335-5p, miR-144, miR-138-5p, miR-219, miR-142, miR-153, miR-299, miR-600, and miR-129-5p [21] [22] [23] [24] [25] .
Previous meta-analysis pointed out that the increased expression of TUG1 is an unfavorable predictor of cancer [26, 27] . These findings may render TUG1 attractive as targets for therapeutic intervention in cancer. In this review, we summarize the recent original studies that focused on the role of TUG1 in sponging miRNA in cancers (Fig. 1) . We also discuss the carcinogenic or tumor suppressor role of TUG1 and the underlying molecular mechanism of TUG1 in sponging miRNA in the occurrence and development of various cancers (Table 1) . Ultimately, we propose the prospects of using TUG1 as a potential biomarker and a therapeutic target for the treatment of cancer. This review will help readers obtain a more detailed knowledge of the molecular mechanism by which TUG1 sponging miRNA plays its role in cancers, and provide some insights and directions for future cancer research.
TUG1 in Human Cancers

TUG1 and gastric cancer
Gastric cancer (GC) is the fifth leading cause of cancer and the third leading cause of death from cancer, making up 7% of cases and 9% of deaths globally [28] . Despite the continuous improvement in diagnostic techniques and the tremendous advances in perioperative management, there were~986,600 new GC cases and 738,000 deaths worldwide in 2008 [29] . Expression of TUG1 has been detected in GC and non-tumor tissues using RT-qPCR, which is significantly higher in GC tissues than that in the corresponding nontumor tissues. In addition, the high expression of TUG1 in GC patients is positively correlated with invasion depth, the tumor, node, and metastasis (TNM) stage and G0/G1 phase block which can be induced significantly by the knockdown of TUG1 [30] . Baratieh et al. [31] have indicated that the expression level of TUG1 is obviously associated with perineural invasion (P = 0.04) and N-classification (P = 0.023). As a prognostic indicator, TUG1 can also significantly promote cancer cell proliferation through its influence on the cell cycle [31, 32] . The significant roles of miRNAs in Figure 1 . Mechanism of TUG1 and miRNA action in cancers TUG1 competes with mRNA for binding to miRNA. When TUG1 is highly expressed, it is superior in competition, so mRNA and miRNA fail to bind, and miRNA loses its inhibitory effect on mRNA, resulting in high expression of downstream target genes. Upregulation of the target protein promotes cancer. TUG1 acts as a 'molecular sponge' and binds to miR-9, miR-26a, miR-34a-5p, miR-129-5p, miR-132-3p, miR-138-5p, miR-142, miR-144, miR-145, miR-186, miR-212-3p, miR-219, miR-299, miR-300, miR-381, miR-355-5p, and miR-600.
GC biology have been extensively explored in recent years [33] . It has been confirmed that miR-1, miR-20, miR-27a, miR-34, miR-127-3p, miR-129-3p, miR-125a, miR-143, miR-144, miR-145, miR-423-5p, and miR-409 are aberrantly expressed [21, 33, 34] . These miRNAs have been observed to be related to GC progression. Recently, researchers found that TUG1, as an oncogene in GC, could regulate the expression of miR-145-5p, miR-144 and miR-381. TUG1 has binding sites for miR-144, miR-381, and miR-145-5p, which can sponge them to suppress their expression [22, 23, 35] . Furthermore, TUG1 functions as a ceRNA to upregulate c-Met by sponging miR-144, subsequently mediating cell proliferation, apoptosis and invasion in GC cells [22] . In addition, Zhang et al. [23] demonstrated that TUG1 promotes the migration and invasion of GC cells by acting as an endogenous sponge of miR-381 and regulating the expression of the miR-381 target gene SOX4. However, we only know that TUG1 promotes the proliferation and invasion of GC by acting as an endogenous sponge of miR-145-5p. As for its downstream target genes, we know nothing at all [35] . This suggests that we need to explore the complete pathway in future research. These studies indicate that TUG1, as a proliferative regulator, may be a prognostic biomarker and a new target for treatment in human gastric cancer. It means that we can make early diagnosis of gastric cancer by detecting TUG1 and its related miRNAs, which is more sensitive and specific than miRNA alone.
TUG1 and hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a common malignant tumor with high mortality and poor prognosis, which has become the third leading cause of cancer-related death in the world [36, 37] . The poor prognosis of HCC is mainly due to the difficulty of early diagnosis and the lack of effective treatment in the late stage [38] . Recently, mounting evidence suggested that TUG1 can be used as a novel biomarker for HCC progression, which is critical to improve diagnosis and treatment [24, 39] . It has been found that TUG1 is upregulated in HCC, and high expression of TUG1 is significantly associated with tumor size (P = 0. 003) and advanced BCLC stage (P < 0. 01) [39] . Overexpression of TUG1 was revealed to promote cell proliferation and inhibit apoptosis. TUG1 silencing suppresses cell apoptosis and leads to cell cycle arrest at the G0/G1 stage in HCC cells. TUG1 competes with miR-132-3p for binding with Sonic hedgehog (Shh) to facilitate the expression of the Shh protein to activate the hedgehog (Hh) pathway. Moreover, Lv et al. [40] reported that TUG1 is highly expressed in HCC, and it sponges miR-144 directly and increases JAK2 expression to activate the JAK2/STAT3 pathway, leading to proliferation, migration and tumorigenesis of HCC cells (Huh7 and HepG2). He et al. [41] demonstrated that TUG1 functions as a ceRNA to accelerate ZEB1-mediated EMT acquisition by sponging miR-142-3p, subsequently mediating cell proliferation, cell migration, and cell invasion in HCC cells. It is remarkable that the inhibition of TUG1 has been observed to result in a satisfactory response to therapy.
TUG1 and colorectal cancer
Colorectal cancer (CRC) is one of the most common malignant tumors in the USA, with mortality rate ranking the third [42] . TUG1 is significantly overexpressed in CRC cell lines and CRC clinical samples compared with adjacent non-tumor tissues [25, [43] [44] [45] . As downregulation of TUG1 restrains proliferation and promotes migration of CRC cells, TUG1 is proved to serve as a potential oncogene in CRC [43] . Moreover, downregulation of TUG1 by siRNA could inhibit CRC cell proliferation, migration and EMT [44] . Sun et al. [25] found that TUG1 promotes KIAA1199 expression via working as a ceRNA of miR-600. It has first been confirmed that TUG1/miR-600/KIAA1199 promotes CRC cell migration and EMT in vitro and metastasis in vivo. Li et al. [46] reported that TUG1 acts as a ceRNA to sponge miR-186 and governs the expression of the miR-186 target gene CPEB2 in CRC cells. High expression of CPEB2 mediates Methotrexate (MTX) resistance, which prevents its clinical application in cancer therapy. In conclusion, TUG1 regulates the sensitivity of MTX in CRC via miR-186/CPEB2 axis, therefore, TUG1/miR-186/CPEB2 may be a promising therapeutic target in CRC treatment.
TUG1 and bladder cancer
Bladder cancer (BC) is the most common and fatal malignant tumor in the genitourinary system, and it is also a highly invasive cancer [47] . At present, the existing studies have confirmed that TUG1 is highly expressed in BC, and its expression level is related to the grade and stage of BC. Overexpression of TUG1 predicts poor prognosis [48] . Jiang et al. [49] revealed that radiotherapy promotes the expression of TUG1 and HMGB1 in BC cell lines, while TUG1 knockdown inhibits the expression of HMGB1 in BC cell lines. Knockdown of TUG1 enhances the radiosensitivity of BC cells by downregulating HMGB1 expression. The combination therapy of TUG1 knockdown and radiotherapy may provide a better strategy for patients with radiation-resistant BC [50] . Moreover, TUG1 binds to miR-142 to regulate ZEB2 expression, which promotes the cell proliferation and migration in BC. In contrast, knockdown of TUG1 inhibits Wnt/β-catenin pathway activation by downregulating ZEB2 expression [50] . Likewise, TUG1 functions as a ceRNA to upregulate ZEB2 by sponging miR-145, which provides new insights into molecular-regulation EMT and radioresistance of BC [51] . However, it has recently been found that TUG1 can serve as miR-29 sponge to inhibit the expression of miR-29c, thereby promoting cell proliferation, migration and metastasis of BC cell lines T24 and EJ [52] .
TUG1 and breast cancer
Breast cancer is one of the most common malignancies among women worldwide, and it is also the leading cause of cancer-related death in women. Subsequent studies found that TUG1, which is highly expressed in 100 breast cancer tissues, is associated with adverse features such as tumor size, distant metastasis, and TNM staging [53] . In MCF-7 cells, Zhao et al. [54] found that downregulation of TUG1 significantly inhibits proliferation, suppresses cell cycle progression, and promotes apoptosis. In addition, TUG1 upregulates the expression of MTHFD2, which was recently identified as a drug target that blocks cell migration and invasion of breast cancer by suppressing the expression of miR-9 [54, 55] . However, TUG1 expression is significantly repressed in triple negative breast cancer (TNBC) tissues compared with normal tissues and normal breast epithelial cell line and cell lines of other subtypes of breast cancer [56] . TUG1 has been shown to contribute to chemotherapy sensitivity of TNBC cells by inactivating WNT signaling pathway via sponging miR-197 and regulating nemo-like kinase (NLK) expression. Therefore, high expression of TUG1 in TNBC patients means a good prognosis. In conclusion, TUG1 plays a vital role in breast cancer and it can be a new therapeutic target for breast cancer.
TUG1 and pancreatic cancer
Pancreatic cancer (PC) is one of the most common malignant tumors in the digestive tract, and its incidence is increasing year by year [57] . Once diagnosed with PC, the prognosis of patient is poor and the 5-year survival rate is lower than 5% [58] . Based on the results of lncRNA expression array analysis of RT-qPCR and clinical PC samples, Zhao et al. [59] confirmed that lncRNA TUG1 is upregulated in PC cell lines and tissues and acts as an oncogene in the development of PC. High expression of TUG1 is correlated with poor prognosis. Qin et al. [60] showed that TUG1 is highly expressed in three PC cell lines, but the expression level is altered. The expression level in SW1990 cells is higher, and the expression levels in BxPC3 and PaTu8988 cells are relatively lower. Further studies showed that TUG1 competitively adsorbs miR-382, and its Endometrial cancer Upregulated Angiogenesis Oncogenic miR-299↓, miR-34a-5p↓ [88] target EZH2 is significantly upregulated. Conversely, downregulation of TUG1 and overexpression of miR-382 lead to a significant downregulation of EZH2, thereby inhibiting molecules, cell cycle regulators and tumor suppressor genes involved in the EMT process [60] . Therefore, the effect of TUG1 on PC cell proliferation, migration and EMT formation may be less attributable to the role of ceRNA as a competitive binding to miR-382. The detailed mechanism of TUG1 function in PC deserves further study. TUG1 may be useful as potential targets for novel therapies of PC.
TUG1 and cervical cancer
Cervical cancer (CC) is one of the most common malignant tumors in women worldwide [62] . Hu et al. [62] detected the expression of TUG1 using qRT-PCR in 40 cases of cervical cancer, 21 CIN samples and 19 normal samples, which showed that the expression of TUG1 is significantly upregulated in cervical cancer and the expression level of TUG1 increases from normal tissue to CIN and then to tumor stage. Mechanistically, Jie et al. [63] demonstrated that TUG1 works as a ceRNA in CC cells to sponge and suppress miR-138-5p and positively regulates the miR-138-5p target gene SIRT1. Highly expressed SIRT1 promotes the expression of c-myc, β-catenin, and cyclin D1, inhibits the expression of E-cadherin, thereby activating the Wnt/β-catenin signaling pathway to promote proliferation and invasion and inhibit apoptosis. In conclusion, TUG1 plays an oncogenic role in cervical cancer ( Table 1) , and TUG1/miR-138-5p/SIRT1/Wnt/β-catenin axis may become a new entry point for the treatment of cervical cancer.
TUG1 and osteosarcoma
Osteosarcoma (OS) is the most common primary malignancy in adolescents and is associated with poor prognosis and high disability rates in adolescents [64, 65] . Despite significant advances in adjuvant therapy, including radiotherapy and chemotherapy, the life expectancy of patients with OS who still have local recurrence and distant metastasis remains low [66] . Therefore, biomarkers for further identification of OS progression are critical for the early diagnosis and treatment of OS. Early studies by Zhang et al. [67] suggested that TUG1 is highly expressed in OS tissues compared with normal tissues, and it has been confirmed by cytological experiments that exogenous silencing of TUG1 can inhibit the proliferation of OS cells and induce apoptosis. Recently, the result of a Chi-square test showed a correlation between high TUG1 expression in OS and larger tumor size (P = 0.037) and advanced TNM stage (P = 0.025) [68] . TUG1 is involved in multiple classical signaling pathways in the development of OS, and the main mechanism is that TUG1 functions as a ceRNA that binds to miRNA. Xie et al. [69] found that TUG1 directly interacts with miR-212-3p and suppresses its expression in OS cells, and the low expression of miR-212-3p loses the negative regulation of its downstream target gene FOXA1. In addition, high expression of TUG1 in OS can also downregulate the expression of miR-132-3p by endogenous sponge adsorption mechanism, and the low expression of miR-132-3p loses the negative regulation of its downstream target gene sex determining region Ybox 4 (SOX4) [70] . Accumulated evidence has suggested that SOX4 is considered as an oncogene in a variety of cancers, including OS [71] . Cao et al. [72] demonstrated that TUG1 functions as a ceRNA to upregulate EZH2 by sponging miR-144-3p to promote the Wnt/ β-catenin pathway activation in OS cells (MG63, U2OS, HOS, and Saos-2). Overexpression of TUG1 could reduce the expression of miR-153 in OS tissues and cell lines, thereby contributing to the development of OS. In contrast, knockdown of TUG1 can suppress the survivability, colony formation and invasion of OS in vitro [73] . Wang et al. [74] confirmed that TUG1 is the target of miR-335-5p by luciferase assay, regulating the expression of Rho-associated coiled-coil-containing protein kinase 1 (ROCK1) to promote migration and invasion in OS. Moreover, Xie et al. [75] found that TUG1 sponges miR-9-5p and regulates POU2F1 expression. The latest research confirmed that high expression of TUG1 in OS can downregulate the expression of miR-219a-5p by endogenous sponge adsorption mechanism, thereby further upregulating PIK3CA and activating the AKT signaling pathway, consequently promoting proliferation, migration, and invasion [76] . In summary, TUG1 acts as an oncogene in OS cells and plays a crucial role in the early diagnosis and treatment of OS ( Table 1) . However, whether there is a mutual interaction between different molecular mechanism and pathways remains to be explored.
TUG1 and glioma
Glioma is a joint malignant tumor, accounting for 80% of all malignant brain tumors [77] . Recent studies have shown that the expression of TUG1 in non-tumor tissues is significantly higher than that in glioma tissues, while miR-26a is obviously expressed in cancer cells [78, 79] . Further correlation analysis showed that the low expression of TUG1 is closely related to glioma and its WHO grade, pathological stage and tumor size [78] . Moreover, TUG1 regulates apoptosis of glioma cells by activating caspase-3, caspase-9, and downregulating the expression of Bcl-2, leading to the promotion of cell apoptosis [78] . Notch signaling pathway predominantly regulates TUG1 expression in glioma cells. Zhao et al. [79] found that TUG1 acts as a miR-26a endogenous sponge with a positive regulatory effect on phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a direct and functional downstream target of the tumor suppressor miR-26a. Through the regulatory mechanism of TUG1/miR-26a/PTEN, TUG1 can be upregulated to reduce cell proliferation and promote cell apoptosis, thus finally to treat glioma, however further studies are needed to confirm these hypotheses. Glioblastoma (GBM) is the most invasive glioma subtype with the 5-year survival rate of <5% [80] . The expression level of TUG1 was revealed to be high in GBM tissues when compared to that in the adjacent normal tissues of 120 GBM patients by qRT-PCR [81] .
Further research on the mechanism demonstrated that TUG1 promotes tumor-induced angiogenesis and VEGF expression by acting as an endogenous sponge of miR-299 and regulating the expression of the miR-299 target gene VEGFA [81] . VEGFA acts as a regulatory factor in TUG1-mediated tumor angiogenesis. Since TUG1 has a direct binding site to miRNA, when TUG1 is silenced it leads to the binding of miRNA to VEGFA mRNA, and thereby inhibits the expression of VEGFA protein. As a result, knockdown of TUG1 can inhibit tumor-induced endothelial cell proliferation, migration, and tube formation, as well as reduce spheroid-based angiogenesis ability.
TUG1 in other cancers
TUG1 is abnormally highly expressed in a variety of other cancers, including prostate cancer [82] , thyroid cancer (TC) [83] , gallbladder carcinoma [84] , intrahepatic cholangiocarcinoma (ICC) [85] , oral squamous cell carcinoma (OSCC) [86] , malignant melanoma (MM) [87] , and endometrial cancer (EC) [88] . Recent studies have indicated that TUG1, as a functional oncogene in prostate cancer development, negatively regulates the expression of miR-26a to promote migration, invasion and proliferation of prostate cancer cells [82] . In TC, high expression of TUG1 competes with EZH2 for binding to miR-145, which upregulates EZH1 expression, thereby promoting cell proliferation, migration, metastasis, and EMT phenotype formation [83] . In addition, these findings confirmed that TUG1 promotes gallbladder carcinoma cell proliferation, metastasis and EMT progression by acting as ceRNA to bind miR-300 [84] . In ICC, TUG1 acts as ceRNA that can 'attract' miR-145 to prevent the degradation of Sirt3 mRNA and increase the expression of Sirt3 and GDH proteins, thereby promoting cancer progression and regulating glutamine metabolism [85] . Furthermore, TUG1 binds to miR-219 in the form of ceRNA, thus, promoting the expression of its downstream functional target FMNL2 (formin-like 2) and accelerating tumor cell proliferation, migration, and invasion in OSCC [86] . In MM, TUG1 upregulates the expression of Bcl-2, MMP-9 and cyclin D1 (cyclin D1) by binding to miR-129-5p, thus, inhibiting apoptosis and promoting cell growth [87] . TUG1 can also sponge miR-299 and miR34a-5p to regulate VEGFA expression in endometrial cancer, thereby promoting of cell proliferation in EC [88] .
However, the sponge role of TUG1 may exist in other cancers. Chiu et al. [89] revealed that TUG1 acts as an oncogene in ovarian cancer (OV). TUG1 silencing reduces the growth of OV cells (SKOV-3 and OVCAR-3 cells), and the expression level of miR-381 is downregulated in OV tissues and cell lines [90] . Therefore, this TUG1 sponging miR-381 might be a mirage in OV. Moreover, TUG1 acts as a tumor oncogene by promoting malignant processes of small cell lung cancer (SCLC) and plays the role of a tumor suppressor gene in non-SCLC (NSCLC) [91] . Therefore, TUG1 may act as ceRNAs that sponge specific miRNAs and antagonize their functions in SCLC and NSCLC.
Conclusion
LncRNAs are one of the research hotspots in biological and medical field in recent years. LncRNAs are important molecules in cell development and are involved in a series of cancer progression. TUG1, as a novel type of lncRNA, is an essential molecule involved in numerous biological processes. TUG1 is highly expressed in most cancers and plays the role of oncogene, promoting cancer cell proliferation, migration, metastasis, and the inhibition of apoptosis, but low expression of TUG1 acts as a tumor suppressing gene in glioma. TUG1 has the specificity of cancer histology, and its expression level is not same in a variety of cancers, even the expression level of different cell lines of the same cancer are diverse. In conclusion, TUG1 can be a diagnostic tool for cancer at an advanced stage. TUG1 has been shown to play significant gene-regulatory roles through a variety of mechanisms in various cancers. Numerous related studies demonstrated that the interaction between TUG1 and microRNA plays a major role in tumorigenesis. TUG1 can compete with miRNA for binding to the 3′-UTR of target mRNAs, leading to the negative inhibition of miRNA and the activation of target protein. TUG1 acts as a 'molecular sponge' and binds to miR-9, miR-26a, miR-34a-5p, miR-129-5p, miR-132-3p, miR-138-5p, miR-142, miR-144, miR-145, miR-186, miR-212-3p, miR-219, miR-299, miR-300, miR-381, miR-355-5p, and miR-600. However, the specific mechanism of how TUG1 interacts with miRNA to regulate cancer development, which has a therapeutic effect, remains unknown. The study of the mechanism of TUG1 in cancer is still in the preliminary exploration stage.
Since most cancer patients are diagnosed at an advanced stage, traditional treatments are often ineffective in a large number of patients, leading to high cancer mortality. Therefore, establishing a strategy for early diagnosis of cancer can significantly reduce cancer mortality. The discovery of TUG1 has immeasurable potential for cancer diagnosis. At the same time, it provides a fresh perspective on the precise biological effects and molecular mechanism of TUG1 in cancer. For example, we can gain knowledge of the targets that modulate TUG1 expression, thereby developing interfering drugs which inhibit the binding of TUG1 to miRNA, and even knockout TUG1. Of course, if we want to implement these settings, a lot of basic studies and clinical research are needed. We believe that TUG1 will bring more surprises to us in the near future.
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